Correspondence 0001683168-24-005128 from Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp.
Date: July 30, 2024 · CIK: 0001533040 · Accession: 0001683168-24-005128
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281052
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Registration Statement on Form S-1 Filed July 26, 2024 File No. 333-281052 Request for Acceleration of Effective Date
Dear Mr. Buchmiller:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on August 1, 2024, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Amanda Brown of Hogan Lovells US LLP at (267) 675-4683. Also, please notify Ms. Brown when this request for acceleration has been granted.
Very truly yours,
PHIO PHARMACEUTICALS CORP.
Show Raw Text
CORRESP 1 filename1.htm PHIO PHARMACEUTICALS CORP. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 July 30, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed July 26, 2024 File No. 333-281052 Request for Acceleration of Effective Date Dear Mr. Buchmiller: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on August 1, 2024, or as soon thereafter as possible. Please direct any questions or comments concerning this request to Amanda Brown of Hogan Lovells US LLP at (267) 675-4683. Also, please notify Ms. Brown when this request for acceleration has been granted. Very truly yours, PHIO PHARMACEUTICALS CORP. By: /s/ Robert J. Bitterman Name: Robert J. Bitterman Title: President and Chief Executive Officer cc: Amanda Brown, Hogan Lovells US LLP